Waters Corporation

Waters Corporation, a maker of products used in drug discovery and development, shows a positive Earnings ESP of +0.45% ahead of its next earnings report expected on August 4, 2026. The company has an established record of topping earnings estimates, with an average surprise of 8.77% over the past two quarters. For the most recent quarter, Waters reported earnings of $2.70 per share versus a consensus estimate of $2.31, a surprise of 16.88%, while the previous quarter saw earnings of $4.53 per share against a $4.50 estimate. The stock holds a Zacks Rank #3 (Hold), and the combination of a positive Earnings ESP and a Zacks Rank #3 or better has historically produced a positive surprise nearly 70% of the time.

Waters Corporation delivered the strongest first-quarter performance among the ten research tools and consumables stocks tracked, with revenues of $1.27 billion, up 91.5% year on year and beating analysts' estimates by 4.5%. The company also posted the biggest analyst estimate beat, highest guidance raise, and fastest revenue growth among its peers. Avantor reported revenues of $1.58 billion, flat year on year but exceeding expectations by 2.7%, while Revvity's revenues of $686.9 million, up 9.3% year on year, fell short of estimates by 2.6% and came with full-year guidance that missed expectations. Sotera Health Company posted revenues of $280 million, up 10% year on year and topping estimates by 3.6%, and Bio-Techne reported revenues of $311.4 million, down 1.5% year on year and missing estimates by 1.6%. Overall, the group's revenues beat consensus estimates by 1.3%, and next-quarter revenue guidance was 2% above expectations, with share prices up 22.5% on average since the latest earnings results.

The ten research tools and consumables stocks tracked reported mixed first-quarter results, with aggregate revenues beating analysts' consensus estimates by 1.3% and next-quarter revenue guidance coming in 2% above expectations. Mettler-Toledo posted revenues of 947.1 million dollars, up 7.2% year on year and slightly ahead of estimates, though the quarter was mixed overall. Waters Corporation stood out with revenues of 1.27 billion dollars, a 91.5% year-on-year surge that exceeded estimates by 4.5%, and it delivered the biggest analyst estimate beat, highest guidance raise, and fastest revenue growth among its peers. Revvity's revenues of 686.9 million dollars, up 9.3% year on year, missed estimates by 2.6% and it issued full-year guidance below expectations, marking the weakest performance against estimates in the group. Sotera Health Company reported revenues of 280 million dollars, up 10% year on year and beating estimates by 3.6%, while Bruker's revenues of 823.4 million dollars, up 2.7% year on year, topped estimates by 3.4%. Share prices of the group have risen 20.8% on average since the latest earnings results.

IMU Biosciences has selected Waters Corporation as a strategic partner to accelerate its AI-driven High Definition Immunology platform. The collaboration will combine Waters Biosciences' flow cytometry and single-cell technologies, including BD FACSDiscover Cell Analyzers and BD Rhapsody Instruments, with IMU's proprietary machine learning analytics that can measure over 100 million data points from a single blood sample. IMU is building what it calls the world's largest immune dataset, and the partnership supports its expansion through large-scale studies aimed at establishing a universal standard for immune profiling. The companies intend to pursue additional translational research for novel biomarker discovery and presented system-level immune profiling data at the CYTO 2026 annual meeting.